Evidence map›Paper›PMID 36353492›Full record

ArticleFrontiers in pharmacology2022

Catalpol ameliorates CFA-induced inflammatory pain by targeting spinal cord and peripheral inflammation.

Baoxia Zhao, Jie Fu, Huadong Ni, Longsheng Xu, Chengfei Xu, Qiuli He, Chaobo Ni, Yahui Wang, Jiao Kuang, Mengjie Tang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Betanin fromBiomedicines · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Quantum Health AcceleratorBrain sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Baoxia ZhaoSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jie FuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Huadong NiDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Longsheng XuDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Chengfei XuDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Qiuli HeDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Chaobo NiDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Yahui WangDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Jiao KuangDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Mengjie TangDepartment of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing Or The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Qiyang ShouSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Ming YaoSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
First Hospital of Jiaxing · CNJiaxing University · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic, inflammatory pain is an international health concern that severely diminishes individuals' quality of life. Catalpol is an iridoid glycoside derived from the roots of Rehmannia glutinosa that possesses anti-inflammatory, antioxidant, and neuroprotective properties for the treating multiple kinds of disorders. Nevertheless, catalpol's impacts on inflammatory pain and its potential methods of action are still unclear. The purpose of this investigation is to determine the mechanism of catalpol to reduce the inflammatory pain behaviors in a rat model with complete Freund's adjuvant (CFA). Catwalk, Von-Frey, and open field testing were performed for behavioral assessment. Western blot analysis and real-time quantitative PCR (RT-PCR) were employed to identify variations in molecular expression, while immunofluorescence was utilized to identify cellular localization. Catalpol effectively reduced CFA-induced mechanical allodynia and thermal hyperalgesia when injected intrathecally. Moreover, catalpol can regulate the HDAC4/PPAR-γ-signaling pathway in CFA rat spinal cord neurons. Meanwhile catalpol significantly decreased the expression of the NF-κB/NLRP3 inflammatory axis in the spinal cord of CFA rats. In addition, both

Indexed as

astrocyte activationcatalpolHDAC4/PPAR-γ -signaling pathwayinflammatory painNF-κB/NLRP3 inflammatory axisperipheral pain

Identifiers

PMID36353492
PMCPMC9637921
OpenAlexW4307274069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.